Press Releases

IM8 90-Day Subscribers Unlock SuperPower Blood Testing for $49 — A 75% Saving on the Standard $199 Price. IM8 and Superpower create the first closed-loop system in consumer health – connecting clinical-grade supplementation with 100+ biomarker blood testing.

NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (PRE) (“Prenetics” or the “Company”), a leading consumer health sciences company and parent of the IM8 premium health and longevity brand, today announced the Company will participate in the 38th Annual ROTH Conference being held

Management and Board Have Collectively Committed Up to $42.75 Million to Prenetics Stock  Backed by $164 Million in Total Adjusted Liquidity, Zero Debt IM8 Targeting $180M to $200M in 2026 Full Year Revenue, and a Clear Path to Adjusted EBITDA Profitability by Q4 2027 NEW YORK, March 06, 2026

-  CEO Danny Yeung makes personal investment in this round of approximately $750,000, up from investment of approximately $502,000 in November 2025 NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading consumer health sciences

Up to 733% Greater Potency Across 11 Key Nutrients, Including New Saffron Nootropic and Bioactive Vitamin Forms Two New Flavours — Mango + Passionfruit and Lemon + Orange Same Price for New and Existing Customers Full Supplement Facts Available at im8health.com/products/essentials NEW YORK, Feb.

Final Milestone in Strategic Transformation Positions Company to Accelerate IM8 Global Expansion with Zero Debt Q4 and Full-Year 2025 Financial Results to be Announced on February 18, 2026 NEW YORK, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the

Total Revenue Increased  480% to $92.4 million for Full Year 2025, Q4 Revenue reached $36.6 million IM8 Reaches $10 Million in Monthly Revenue in December 2025, Achieving $120M ARR Milestone Strategic Transformation Completed with Divestitures and Focus on IM8 Total Adjusted Liquidity 2 of

Appointment Strengthens Board with Deep Clinical and Commercial Expertise in Healthspan Optimization, Aligning with IM8 Growth Strategy NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading consumer health sciences company and

Final Milestone in Strategic Transformation Positions Company to Accelerate IM8 Global Expansion with Zero Debt Q4 and Full-Year 2025 Financial Results to be Announced Pre-Market on February 18, 2026 NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or

Ollie Bearman becomes the latest elite athlete to invest in NASDAQ:PRE, underscoring a deep belief in the brand’s mission and products. IM8, co-founded by David Beckham, continues to attract top-tier athletes who prioritize scientifically validated and trusted nutritional support.